| Pioglitazone for the Treatment of Major Depressive Disorder Comorbid with Metabolic Syndrome
Gender & Age: Women & Men, ages 18-70
Diagnosis: Major Depressive Disorder and Metabolic Syndrome**
Medications: All participants will be taking pioglitazone, an FDA approved medication for the treatment of high blood sugar.
Study Details: Study may last up to 24 weeks. Visits are typically once every week or every other week and last at least 1 hour long once enrolled. All potential participants will be screened for metabolic syndrome at their initial study visit. Participants cannot be suffering from Heart Failure.
Contact: David E. Kemp, MD @ 216.844.2863
**Metabolic Syndrome refers to a group of medical risk factors found in individuals that may be overweight, have high blood pressure or elevated cholesterol levels, and may have family members with heart disease and or diabetes. For more information on metabolic syndrome, click here.
Quetiapine XR Monotherapy in the Treatment of Major Depressive Disorder with Comorbid Generalized Anxiety Disorder – PI: Keming Gao, MD, PhD
Gender & Age: Women & Men, ages 18-70
Diagnosis: Major Depressive Disorder, currently in a depressive episode with generalized anxiety
Medications: Patients will take Quetiapine XR or placebo (50-50 chance of getting placebo).
Study Details: The study will last for 8 weeks and the participant will be seen weekly for an hour. If the participant doesn’t do well during the study, he or she will discontinue the study. For inclusion into this study, the participant must not have tried Quetiapine more than 50 mg/day.
Contact: Keming Gao, MD, PhD / Keming.Gao@UHhospitals.org
Ad: (click
for ad)
Ad: (click
for ad)
Quetiapine XR Monotherapy in the Treatment of Comorbid Generalized Anxiety Disorder in Bipolar Depression with or without Substance Use Disorder
Gender & Age: Women & Men, ages 18-70
Diagnosis: Bipolar Disorder (type I or II), currently in a depressive episode with generalized anxiety
Medications: Patients will take Quetiapine XR or placebo (50-50 chance of getting placebo).
Study Details: The study will last for 8 weeks and the participant will be seen weekly for an hour. If the participant doesn’t do well during the study, he or she will discontinue the study. For inclusion into this study, the participant must not have tried Quetiapine more than 50 mg/day.
Contact: Mary Beth Serrano/216.844.2817/Marybeth.Serrano@UHhospitals.org or Keming Gao/216.844.2865/Keming.Gao@UHhospitals.org
Ad: (click
for ad)
Ad: (click
for ad)
Lithium in Moderate Use Doses for Bipolar Disorder (LiTMUS): A Randomized Controlled Effectiveness Trial
Gender & Age: Women & Men, ages 18 & older
Diagnosis: Bipolar Disorder (type I or II), currently experiencing a mood episode (depression, mania, hypomania, or a mixed state)
Medications: Optimized Treatment (OPT) versus OPT plus Lithium
Study Details: Up to 6 months long, visits are once every 2 weeks for the first 2 months and then monthly thereafter.
Contact: Carla Caonroy at 216.844.2871 or Carla.Conroy@UHhospitals.org
A Long-Term, Observational, Multi-Center
Patient Outcome Registry to Collect Data in Patients for the
Scientific Study of Causes, Treatments and Illness Course of
Bipolar Disorders
Gender & Age: Women & Men, ages 16
& older
Diagnosis: Bipolar Disorder or Unipolar Major
Depression
Medications: No particular treatment is required
Study Details: The purpose of this Registry
is to collect demographic information on a wide cross section
of patients with a mood disorder, and to collect information
that can be used for future research study recruitment. Participation
in the Registry does not effect regular clinical treatment.
We will inform participants of the option to enroll in other
studies carried out as a part of the Center. We will also send
the Center newsletter as it is published, approximately once
every 3 months. We will contact Registry participants by email,
mail, or telephone calls depending on preference.
Contact: 216.844.2863
Ad: (click
for ad)
Long-Term, Observational, Multi-Center Patient Outcome Registry to Collect Data in Patients with Treatment Resistant Depression (TRD) – PI: Prashant Gajwani, MD
Gender & Age: Women & Men, ages 16 & older
Diagnosis: Major Depressive Disorder (MDD) or Bipolar Disorder (type I or II), with Treatment Resistant Depression (TRD), defined as being in the current episode of depression for the past 2 years or longer.
Medications: Patients decide on their medications (treatment as usual), and at enrollment are assigned to one of two groups (VNS or non-VNS) depending on whether they have decided to have VNS implanted or not. No study interventions are required in this Registry.
Study Details: Either 2 or 5 years long, visits are typically once every 3 months for the first year, and then once every 6 months.
Contact: 216.844.2863
Risk and Resilience Factors for Combat-Related Posttraumatic
Psychopathology and Post Combat Adjustment
Since early 2005 Joseph Calabrese M.D. and the Center for Bipolar
Disorder have been working with Congresswoman Marcy Kaptur and
the Department of Defense on an exciting proposal entitled the
Kaptur DoD/DVA Mental Health Initiative. The general objective
of this initiative is to evaluate the relationships between
resilience and risk factors, both cross-sectionally and longitudinally,
before, during, and after treatment within the DVA. The primary
research project for this initiative was garnered through a
2006 Department of Defense allocation and is entitled “Risk
and Resilience Factors for Combat-Related Posttraumatic Psychopathology
and Post Combat Adjustment.
This primary project is designed to study the relationships
between 1) pre-existing mental illness/substance use disorders,
2) deployment to Operation Iraqi Freedom (OIF) or Operation
Enduring Freedom (OEF), and 3) post-deployment related mental
health and overall psychosocial adjustment. The proposed study
will evaluate several groups of the Ohio National Guard: those
deployed to OIF (Iraq, Kuwait, or Qatar), those deployed OEF
(Afghanistan), those deployed to other theaters (Bosnia, Turkey,
Uzbekistan, Kosovo, on a ship, or other), those deployed domestically,
and those not deployed. This project is designed to enroll up
to 3,000 members of the Ohio National Guard and Reserves beginning
in 2007/2008. Research visits will be conducted at time of enlistment,
90-180 days post-deployment, and then every 12 months for a
minimum of 10 years.
For more information on this ongoing research project, please
click here.
|
